CD8A and neoplasm: His team use Glycoprotein - A repetitions predominant antibody treatment to reduce the typical TGF signaling pathway in tumor-infiltrating immune cells, prevent T cell exhaustion, and promote CD8+ T cell migration to TME in a CXCR3-dependent manner to enhance anti-tumor effects.